RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell ADRC -enriched fat grafting for reconstruction of the breast after cancer surgery. The majority of patients underwent radiation prior to the procedure, creating an unfavorable ischemic environment for which breast reconstruction with ADRC-enriched fat grafting appears to be ideally suited. The procedure can be performed on an outpatient basis.
A lumpectomy is less drastic than having a mastectomy, but it leaves you with a scar and a dimple where a smooth, full curve used to be. The breast can also end up much smaller causing significant breast asymmetry in some women. This asymmetry is often exacerbated by the contraction shrinkage caused by the radiation therapy that usually follows lumpectomy.
RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell ADRC - enriched fat grafting for reconstruction of the breast after cancer surgery. The majority of patients underwent radiation prior to the procedure, creating an unfavorable ischemic environment for which breast reconstruction with ADRC-enriched fat grafting appears to be ideally suited. Key findings of the trial were:.
The views expressed are those of the author s and are not necessarily those of Scientific American. You have free article s left. Already a subscriber? Sign in.
August 6, The number of breast enlargement operations performed in the US, for both augmentation and reconstruction purposes, has radically increased in the last decade. At the same time the number of operations to remove implants has also risen and given the potential surgical complications and health consequences of such surgery, many doctors find this trend troubling. Inoverbreast augmentations and reconstructions were performed in the United States, making them the most common type of cosmetic surgery and almost tripling the number of operations in
Women who think their derriere is too big and their chest is too small might soon have an option to reverse that equation. Fat cells are sucked out of adipose tissue, then filtered using technology developed by Cytori Therapeutics to increase the ratio of fat stem cells, and then injected into the breast. The treatment, being commercialized in partnership with GE Healthcare, is currently in limited use among women who have lost breasts to cancer.
Members of the Global Cancer Consortium believe that progress occurs through collaboration which can occur through improved information. Its Cancer Progress Report reaches thousands of investors and industry professionals. Cytori Therapeutics NASDAQ: CYTX is a leading global innovator in the emerging field of regenerative medicine using adipose fat tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
The company, which calls its procedure RESTORE, said that clinical outcomes reported at the Association of Breast Surgery Conference in Manchester, England, earlier this month suggest the procedure is a viable breast reconstruction option. The patients were treated between September and Novemberand 82 percent 19 patients reported good to excellent results, with a mean satisfaction score of 5. The study findings also showed a low complication rate.
Cytori Therapeutics, Inc. System breast reconstruction product and provide an update on the start of the Celution? A replay will be available on the Company ' s website approximately one hour following the live presentation.